Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Astrid Plenker"'
Publikováno v:
Clinical Drug Investigation. 22:43-52
Objective: To assess the efficacy and safety of desloratadine in the treatment of seasonal allergic rhinitis (SAR) in the clinical setting. Design and Setting: The postmarketing surveillance study was performed in Germany in 47 953 outpatients requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc095dd92cbab62259848324254ee675
https://doi.org/10.2165/00044011-200222002-00005
https://doi.org/10.2165/00044011-200222002-00005
Publikováno v:
International Clinical Psychopharmacology. 12:S17-S24
Electro-oculogram (including saccadic eye movements), auditory-evoked potentials and visual analogue scales for a subjective impression of effects were used to evaluate some pharmacodynamic properties of RS-8359. In the electro-oculogram, administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b39f424364f483247dd8432ce98fff
https://doi.org/10.1097/00004850-199709005-00004
https://doi.org/10.1097/00004850-199709005-00004
Publikováno v:
International Clinical Psychopharmacology. 12:S25-S30
The potential liability of RS-8359 for the 'cheese' effect that is characteristic of the classical monoamine oxidase inhibitors has been compared with placebo and moclobemide in the tyramine test. Both RS-8359 and moclobemide reduce the dose of tyram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa09a5e4be2a575cd207dc61a6c4146e
https://doi.org/10.1097/00004850-199709005-00005
https://doi.org/10.1097/00004850-199709005-00005
Publikováno v:
International Clinical Psychopharmacology. 12:S11-S16
RS-8359 is very rapidly absorbed, metabolized and distributed following oral dosing, with significant concentrations of both parent drug and its principal metabolite appearing in plasma within 15 min. Plasma levels were linearly related to doses of u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c6e4c535709d765b254fd3757e9e53
https://doi.org/10.1097/00004850-199709005-00003
https://doi.org/10.1097/00004850-199709005-00003
Publikováno v:
International clinical psychopharmacology. 12
RS-8359 is a new reversible inhibitor of monoamine oxidase A (RIMA). With a selectivity ratio of about 2200 for the A:B enzyme types, it is one of the most specific of this class of compounds. As a result, it shows relatively little effect upon blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f36b2062e4ebc185bdf00626b186fc
https://pubmed.ncbi.nlm.nih.gov/9466163
https://pubmed.ncbi.nlm.nih.gov/9466163
Publikováno v:
International Clinical Psychopharmacology. 12:S31
The safety, tolerability and a preliminary assessment of the efficacy of the new reversible inhibitor of monoamine oxidase A, RS-8359, were evaluated in two studies in hospitalized, depressed patients. Daily doses of 100 and 200 mg divided into two e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1931e9738d43310412d2fc152afe073c
https://doi.org/10.1097/00004850-199709005-00006
https://doi.org/10.1097/00004850-199709005-00006